1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Perrigo Delivers ‘Remarkable Quarter’ As OTC Birth Control Waits In Wings

Opill Would Be The First OTC Daily Contraceptive Available In The US, If Approved

 
• By Chloe Kent

Perrigo delivered second-quarter results which CEO Murray Kessler described as “truly remarkable” as it lined up its oral contraceptive Opill (0.075-mg norgestrel) for OTC designation.

Pack of contraceptive pills against pink background
Opill would be the first contraceptive licensed for OTC use in the US • Source: Shutterstock

Perrigo’s impressive second quarter saw the company complete several key milestones in its transition to an entirely self-care pharmaceutical firm, closing its multi-billion-dollar takeover of HRA Pharma and completing its first branded Rx-to-OTC switchover of Nasonex 24HR in the US. In high spirits on the firms Q2 results call, company president and CEO Murray Kessler thanked his team for “a truly remarkable quarter.”

The firm achieved sales of $1.1bn during the quarter, an increase of 14.3% – or 20.2% on a constant-currency basis...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’

 
• By Dean Rudge

A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

More from Business

Dr Reddy’s And Alvotech Team Up On Keytruda Rival

 
• By Dave Wallace

After previously partnering on denosumab, Alvotech and Dr Reddy’s have announced a further alliance to co-develop a biosimilar version of Keytruda (pembrolizumab).

Formycon And Fresenius Launch Partnered Stelara Rival In Canada

 
• By Adam Zamecnik

Several years after the initial signing of their agreement, Formycon and Fresenius Kabi announced the launch of their Stelara biosimilar Otulfi in Canada, adding another key market to their list.

Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’

 
• By Dean Rudge

A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.